Is Quizartinib currently covered by medical insurance?

Quizartinib (Quizartinib), trade name:Vanflyta, is an oral small molecule tyrosine kinase inhibitor targeting FLT3-ITD mutations. It is mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations. The drug exerts anti-tumor effects by inhibiting the FLT3 signaling pathway and blocking the proliferation and survival of leukemia cells.

Globally, quizartinib has been approved in multiple countries. In the United States, the Food and Drug Administration (FDA) approved it in July 2023 for use in combination with standard chemotherapy for induction and consolidation therapy in patients with newly diagnosed FLT3-ITD-positive AML, and as maintenance monotherapy after consolidation therapy. In Japan, quizartinib was approved in 2019 for the treatment of patients with relapsed or refractory FLT3-ITD-positive AML. The European Medicines Agency (EMA) also approved the marketing application for Quizartinib in November 2023.

However, as of now, quizartinib has not been approved by the National Medical Products Administration (NMPA) in mainland China and is therefore not yet available on the domestic market. Since it is not on the market, the drug has not yet been included in China's medical insurance list, and patients need to purchase the drug overseas or through other channels at their own expense. This may bring a greater financial burden to patients who require long-term treatment.

It should be noted that the use of Quizartinib must be carried out under the guidance of a professional doctor. Patients should undergo regular electrocardiogram examinations during use to monitor changes in QTc interval to prevent the occurrence of adverse reactions such as arrhythmia. With the global emphasis on targeted therapy, quizartinib is expected to be approved in China and included in the medical insurance directory in the future, providing new treatment options for domestic FLT3-ITD-positive AML patients.

Reference materials:https://go.drugbank.com/drugs/DB12874